title: Establishment of a Mouse Anti-ovalbumin IgE Monoclonal Antibody That Induces FcɛRII (CD23)-dependent Activation Without FcɛRI-Dependent Activation.
abstract: IgE mainly activates cells via two receptors, FcɛRI and FcɛRII. Blocking antibodies against and animals genetically targeted for these receptors have been successfully used to distinguish between these two activating pathways. In the present study, we investigated whether our newly established anti-ovalbumin (OVA) monoclonal IgE OE-2 induced FcɛRII-dependent activation, but not FcɛRI-dependent activation in vivo and in vitro, in contrast to the previously established anti-OVA IgE OE-1, which stimulated FcɛRI and FcɛRII. The FcɛRI-mediated degranulation of RBL2H3 cells and passive systemic anaphylaxis in mice were induced by OE-1 but not OE-2. On the other hand, the production of nitric oxide by rat peritoneal macrophages and the primary antibody response in mice against co-injected OVA, which were mediated through FcɛRII, were induced and enhanced by OE-1 and OE-2. Differences in the epitopes recognized by OE-1 and OE-2 may partially explain why OE-1, but not OE-2, triggered FcɛRI-dependent activation. OE-1 bridged FcɛRI through effective aggregation with OVA, whereas OE-2 crosslinked the receptor strongly and only moderately upon the addition of an anti-kappa antibody and polymerized OVA, namely, an OVA-conjugated resin, respectively, resulting in degranulation. Our results offer a novel approach for determining the relative importance of FcɛRI and FcɛRII in various IgE-dependent responses by using OE-1 and OE-2.
authors.affiliation: Department of Pharmacology, Kobe Pharmaceutical University , Kobe, Hyogo, Japan .
authors.forename: Kouya
authors.initials: K
authors.lastname: Yamaki
authors.affiliation: Department of Pharmacology, Kobe Pharmaceutical University , Kobe, Hyogo, Japan .
authors.forename: Shin
authors.initials: S
authors.lastname: Yoshino
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics; D000918:Antibody Specificity; D015550:Cell Degranulation / Q000276:immunology; D002460:Cell Line; D000939:Epitopes / Q000737:chemistry / Q000276:immunology; D015870:Gene Expression; D007073:Immunoglobulin E / Q000235:genetics; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology; D008297:Male; D008407:Mast Cells; D051379:Mice; D008811:Mice, Inbred DBA; D009569:Nitric Oxide / Q000096:biosynthesis; D010047:Ovalbumin / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D066329:Protein Aggregates; D011485:Protein Binding; D051381:Rats; D017455:Receptors, IgE / Q000235:genetics / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000939:Epitopes; D066329:Protein Aggregates; D017455:Receptors, IgE; C026408:anti-IgE antibodies; D009569:Nitric Oxide; D007073:Immunoglobulin E; D010047:Ovalbumin